Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al.
Grinblat
Beni
B
Scheinberg
Morton
M
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005528:Foot; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab